BioMedNewsBreaks

WednesdayFeb 24, 2021 10:45 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Agreement for Upcoming Berubicin Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, have entered into an agreement for WPD to obtain Investigational Medicinal Product (“IMP”) classification for Berubicin for its use in upcoming  clinical trials. According to the update, WPD will purchase half of the batch previously manufactured for CNS by BSP Pharmaceuticals for the WPD-201 and WPD-201P studies, planned to begin in the first half of 2021. Berubicin is a novel anthracycline candidate for the treatment of a number…

Continue Reading

WednesdayFeb 24, 2021 10:15 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Announces Receipt of Regulatory Approval Powdery Mildew Bio-Fungicide in Canada

MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has received regulatory approval from Canada’s Pest Management Regulatory Agency (“PMRA”) for use of a powdery mildew bio-fungicide product; the approval covers use of the powdery mildew bio-fungicide suppression treatment on cannabis and hemp products. MustGrow announced more than a year ago that it had completed a definitive licensing agreement to obtain the exclusive treatment from a leading multinational biological and microbial company. The bio-fungicide product, which is not mustard derived, like MustGrow’s other products, is designed to…

Continue Reading

WednesdayFeb 24, 2021 10:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces First Order for Rapid COVID-19 Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has placed an initial order for rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. The test systems, known as COVID-ID Labs, were ordered from XPhyto’s exclusive diagnostic development partner, 3a-diagnostics GmbH ("3a"). The first order consists of 9,600 individual tests; the tests are packaged in 200 kits of 48 tests each. The tests, which should arrive by mid-March 2021, will be used as samples for review and evaluation and will be primarily given to prospective distribution partners and licensees…

Continue Reading

WednesdayFeb 24, 2021 9:45 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Appoints New Chairman of the Board

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced the appointment of James Sapirstein, president and CEO, as chairman of the company’s board of directors, effective immediately. Sapirstein succeeds Edward J. Borkowski, who joined the AzurRx board in May 2015 and has served as chairman since April 2016. Borkowski will remain as lead independent director of the board of directors. “Having served on AzurRx’s board since 2015, I am committed to ensuring a prosperous future for the company,” said Borkowski. “Under James’ leadership, AzurRx has strategically expanded…

Continue Reading

WednesdayFeb 24, 2021 9:32 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes $17.6M Private Placement; Reaches Key Milestones in Developing AI-Driven Model of Ovarian Cancer

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery closed on its previously announced private placement of common stock and warrants. Priced at-the-market under Nasdaq rules, the 9,043,766 shares of common stocks and warrants were issued and sold by the company in order to purchase no more than 4,521,883 shares of common stock in the private placement. The common stock and associated warrants were issued for $1.95 each, with the warrants having an exercise price of $2 per share. The shares are exercisable immediately; however, they do have a five and…

Continue Reading

TuesdayFeb 23, 2021 3:33 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc.’s App Addresses Treatment Barriers

United Medical Equipment (“UME,” “UMEBSNI”) is focused on providing reliable resources and solutions to help health-care systems work smarter, providers work more proficiently, and patients live healthier lives. Essential to any treatment plan are medication management and collaboration between patient and physician. Two large barriers in medication adherence include poor provider-patient communication and inadequate knowledge about a drug (https://ibn.fm/qzXy6). United Medical has developed a medication management solution to address these barriers: a free app available for download on the Apple App Store and Google Play. A recent article discussing the solution reads, “The free seven-day trial version of the Medication…

Continue Reading

TuesdayFeb 23, 2021 10:12 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Present at Cowen 41st Annual Health Care Conference

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics (“DTx”) market, today announced the company’s plans to participate in the upcoming Cowen 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021. According to the update, Dario's CEO, Erez Raphael and Rick Anderson, president and general manager for North America, are scheduled to present in a virtual setting at 11:00 a.m. ET on Monday, March 1, 2021. Interested parties can access the live and archived webcast via the company’s website. To view the full press release, visit https://ibn.fm/nac7n About DarioHealth Corp. DarioHealth is a leading, global digital-therapeutics…

Continue Reading

MondayFeb 22, 2021 3:05 pm

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) E-Tattoo Will Be ‘Next Wave of Innovation for Neurology’

Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. As scientists work to understand what causes Parkinson’s, Alzheimer’s, dementia and other neurological issues, BRSF is making inroads in helping identify root neurological problems. The company has unveiled a new initiative to develop an innovative e-tattoo device for the brain diagnostics market. The Brain E-Tattoo’s graphene-based electrodes are designed for connection to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. The solution enables each patient’s data…

Continue Reading

MondayFeb 22, 2021 2:55 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Transformation as Berubicin Becomes Subject of Active Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. The company’s pipeline includes Berubicin for the treatment of patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently focused on the development and clinical trials of Berubicin for GBM, as well as the potential of addressing other central nervous system malignancies. “The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our…

Continue Reading

MondayFeb 22, 2021 10:46 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://ibn.fm/NqQs7. The report reads, “Processa’s pipeline is constructed of development-stage assets that have substantial legacy human data, where the company believes a new approach (dosing, indication, trial design, etc.) can unlock latent value. Processa’s management (David Young, Questcor) and board (Khalid Islam, Gentium and Fennec) have a history of successful drug reclamation…

Continue Reading